Tempus raises $100 million Series G at $5 billion valuation to expand AI‑driven healthcare

By 2020 Tempus had proven its AI‑driven genomics platform in cancer care, working with thousands of oncologists and claiming the world’s biggest clinical and molecular data repository.

In early 2021 the company closed a $100 million Series G led by Baillie Gifford, Franklin Templeton and others at a $5 billion post‑money valuation, earmarking the funds to expand into diabetes, depression and cardiology while building out its analytical and machine‑learning platform.

Tempus claims a large clinical data library, offers care in oncology, diabetes, depression and cardiology, and has raised $620M since its 2015 launch.

Oncology alone limited the total addressable market for Tempus’s AI platform.

The company’s proprietary data network created a strong competitive advantage that could be leveraged in adjacent therapeutic areas.

Investors valued the platform’s scalability and were willing to fund a broad‑based expansion at a premium valuation.

A large follow‑on round can give a mature biotech the resources to diversify its product line and deepen its data moat, reinforcing long‑term defensibility.

Following the round, Tempus rolled out AI‑powered tests for diabetes and depression, expanded its partnerships with health systems, and continued to grow its data library, reinforcing its position as a leading AI‑driven healthcare platform.